Cassava Sciences, Inc.

Contributing Author

Recent Articles by Cassava Sciences, Inc.

Feb-19	Cassava Announces Closure of U.S. Department of Justice Investigation GlobeNewswire
Jan-13	Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease GlobeNewswire
Dec-23	Cassava Announces Agreement to Settle Securities Class Action Litigation GlobeNewswire
Nov-12	Cassava Reports Q3 2025 Financials Results and Provides Business Update GlobeNewswire
Oct-22	Cassava Sciences Appoints Dawn C. Bir to the Board of Directors GlobeNewswire
Aug-25	Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference GlobeNewswire
Aug-14	Cassava Reports Q2 2025 Financials Results and Provides Business Update GlobeNewswire
Aug-07	Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer GlobeNewswire
Aug-04	Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy GlobeNewswire
Jun-30	Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting GlobeNewswire
May-08	Cassava Reports Q1 2025 Financials Results, Provides Business Update GlobeNewswire